Literature DB >> 32484726

Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study.

Enrica Bersano1,2, Maria Francesca Sarnelli1, Valentina Solara1, Barbara Iazzolino3, Laura Peotta3, Fabiola De Marchi1, Alessio Facchin4, Cristina Moglia3,5, Antonio Canosa3,5, Andrea Calvo3,5, Adriano Chiò3,5, Letizia Mazzini1.   

Abstract

Background: A cognitive impairment, ranging from frontotemporal dementia (FTD) to milder forms of dysexecutive or behavioral dysfunction, is detected in 30-50% of patients affected by amyotrophic lateral sclerosis (ALS) at diagnosis. Such condition considerably influences the prognosis, and possibly impacts on the decision-making process with regards to end-of-life choices. The aim of our study is to examine the changes of cognitive and behavioral impairment in a large population of ALS from the time of diagnosis to a 6-month follow-up (IQR 5.5-9.0 months), and to examine to what extent the progression of cognitive impairment affects survival time and rate of disease progression.
Methods: We recruited 146 ALS patients classified according to revised criteria of ALS and FTD spectrum disorder. In a multidisciplinary setting, during two subsequent visits we examined clinical features with ALSFRS-r score, FVC% and BMI, and cognitive status with an extensive neuropsychological evaluation.
Results: At second examination, one-third of patients showed a worsening of cognitive impairment, namely 88% of ALSbi, 27% of ALSci, 40% of ALScbi, and, interestingly, also 24% of cognitive normal ALS developed a significant cognitive dysfunction. We find that those who changed their cognitive status presented a lower ALSFRS-r score at t1 and a shorter survival time compared to those who did not change, regardless of the type of cognitive impairment.
Conclusion: We show how cognitive disorders in ALS patients can not only be present at diagnosis, but also manifest during disease and influence the progression of motor deficit and the prognosis.

Entities:  

Keywords:  Amyotrophic Lateral Sclerosis; cognitive impairment; fronto-temporal dementia; longitudinal study

Mesh:

Year:  2020        PMID: 32484726     DOI: 10.1080/21678421.2020.1771732

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  5 in total

Review 1.  Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions.

Authors:  Ambika Shandilya; Sidharth Mehan
Journal:  Neurol Sci       Date:  2021-05-21       Impact factor: 3.307

2.  Multimodal in vivo staging in amyotrophic lateral sclerosis using artificial intelligence.

Authors:  Anna Behler; Hans-Peter Müller; Kelly Del Tredici; Heiko Braak; Albert C Ludolph; Dorothée Lulé; Jan Kassubek
Journal:  Ann Clin Transl Neurol       Date:  2022-06-09       Impact factor: 5.430

3.  Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Laura Pasetto; Maurizio Grassano; Silvia Pozzi; Silvia Luotti; Eliana Sammali; Alice Migazzi; Manuela Basso; Giovanni Spagnolli; Emiliano Biasini; Edoardo Micotti; Milica Cerovic; Mirjana Carli; Gianluigi Forloni; Giovanni De Marco; Umberto Manera; Cristina Moglia; Gabriele Mora; Bryan J Traynor; Adriano Chiò; Andrea Calvo; Valentina Bonetto
Journal:  Brain       Date:  2021-12-31       Impact factor: 13.501

4.  Social cognition deficits in amyotrophic lateral sclerosis: A pilot cross-sectional population-based study.

Authors:  Francesca Palumbo; Barbara Iazzolino; Laura Peotta; Antonio Canosa; Umberto Manera; Maurizio Grassano; Federico Casale; Giorgio Pellegrino; Mario Giorgio Rizzone; Rosario Vasta; Cristina Moglia; Adriano Chiò; Andrea Calvo
Journal:  Eur J Neurol       Date:  2022-05-30       Impact factor: 6.288

5.  Case Report: Cognitive Conversion in a Non-brazilian VAPB Mutation Carrier (ALS8).

Authors:  Anna G M Temp; Martin Dyrba; Elisabeth Kasper; Stefan Teipel; Johannes Prudlo
Journal:  Front Neurol       Date:  2021-06-02       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.